LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Inicio・Lista de Acciones・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Cerrado

Sector Salud

57.06 12.43

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

56.84

Máximo

57.57

Métricas clave
By Trading Economics
Ingresos	44M 137M
Ventas	59M 290M
P/B Media del Sector	21.73 104.138
BPA	1.27
Margen de beneficio	47.245
Empleados	373
EBITDA	22M 143M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+27.73 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	582M 7B
Apertura anterior	44.63
Cierre anterior	57.06

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

105 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

50.51 / 51.14 Soporte y Resistencia

Halozyme Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 11:30 UTC

Principales Noticias

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Comparación entre iguales

Cambio de precio

Halozyme Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

27.73% repunte

Estimación a 12 meses

Media 73 USD 27.73%

Máximo 136 USD

Mínimo 51 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Halozyme Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Halozyme Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

50.51 / 51.14Soporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

105 / 389 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.